Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
June 14, 2023 02:30 ET
|
Kymera Therapeutics, Inc.
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor...
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
June 09, 2023 18:00 ET
|
Kymera Therapeutics, Inc.
Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target knockdown in ongoing clinical trials, with no...
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress
June 09, 2023 03:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
Kymera Therapeutics to Participate in Upcoming June Investor Conference
June 01, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
May 22, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253
May 19, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
KT-253 is a novel, highly potent and selective heterobifunctional degrader of the MDM2 oncoprotein with a differentiated profile from small molecule inhibitors in development for the treatment of...
Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium
May 18, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
In the Phase 1 trial, KT-474 showed evidence of robust IRAK4 degradation in blood and skin lesions as well as a systemic anti-inflammatory effect in hidradenitis suppurativa (HS) and atopic dermatitis...
Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update
May 04, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
Phase 1 clinical trial of MDM2 degrader (KT-253) initiated KT-474 (SAR444656) Phase 2 planned to start in 2023;Kymera to present Phase 1 clinical data at EADV Symposium in May Phase 1 trials for...
Kymera Therapeutics to Report First Quarter 2023 Financial Results on May 4
April 11, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
March 01, 2023 07:00 ET
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...